The company promised it will continue to communicate with an open, transparent and honest attitude, solve problems in a legal way in compliance with standards and try to reduce the adverse effects of the situation, according to the report.
The company's second line in Mianyang, Sichuan province, started mass production in July, while work on the third facility commenced in Chongqing last year.
The company's shipment could reach 350 GWh in 2025, almost nine times its figure in 2019, according to Soochow Securities.
The company was drawn into the public eye after a doctor in Guangzhou, Guangdong province, was detained by the Liangcheng police in January claiming he had criminally injured the company by writing in an online article that Hongmao Yaojiu was toxic and the company exaggerated its beneficial effects.
The company said the e-buses in its fleet have a range of 200 km for now. However, this range is expected to increase in the near future as the technology used in e-bus batteries is quickly developing.
The company will also offer more intelligent and integrated cybersecurity systems to solve home, city and national security problems, the company said.
长沙治疗白癜风效果快的医院
The company will invest 2.8 billion yuan over five years in R&D facilities.
The company said earlier that the offshore wind sector aligns with the company's overall business, and it can apply its resources in offshore engineering and experience in offshore operations in the sector. Analysts said the grid connection of the company's first offshore wind power project illustrates CNOOC's ambitions in advancing energy transformation and implementing its green and low-carbon strategy, as the country's State energy giants, including Asia's biggest refiner-China Petroleum and Chemical Corp-and China National Petroleum Corp have all laid out plans to develop renewable projects toward a low-carbon future.
The company saw steady growth in online music paying users in the fourth quarter of 2019, up 47.8 percent year-on-year to 39.9 million, increasing by 4.5 million quarterly, compared with growth of 4.4 million in the previous quarter.
The company's studies also showed new pharmaceutical products are being brought to the China market faster due to related policy reforms, and more are from Chinese companies.